Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD-801 in Advanced Hepatocellular Carcinoma
NCT06418659Phase 1Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Oct 2024
- Primary completion
- Apr 2026
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD-801 in hepatocellular carcinoma (HCC), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Tolerability and Safety and Objective Response Rate (mRECIST) up to 24 months. Started Oct 2024; status: recruiting.
02
Drugs
CD-801
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06418659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06418659.